Monday, December 05, 2011 10:33:03 AM
GENEVA--(BUSINESS WIRE)--CalciTech Ltd. (OTCBB:CLK) announces today that its subsidiary CalciTech Synthetic Minerals Ltd (CSM) has signed an agreement with Mott MacDonald Ltd. of the United Kingdom, a global management, engineering and development consultancy. The company will prepare basic engineering design documentation for a 50,000 tonnes per annum Synthetic Calcium Carbonate (SCC) plant.
The project with CSM will be managed by John Challenger, a Divisional Director of Mott MacDonald’s Nuclear and Process business.
Commenting on the appointment John Challenger said: “Mott MacDonald is pleased to provide engineering design services for the development incorporating CalciTech’s patented technology. We have years of experience in the process industry sector and will provide CSM with an integrated service both for the first plant and for future plants wherever they will be built throughout the world.”
About CalciTech Synthetic Minerals Ltd:
CalciTech Synthetic Minerals Ltd has developed and patented unique technology for the production of Synthetic Calcium Carbonate, “SCC” a specialty material that may be widely used in industrialized parts of the world and is developing operating licensees in these territories, the first being in Europe. With its technological capabilities, CalciTech will continue to develop the product potential into other areas.
About Mott MacDonald Ltd.:
Mott MacDonald of the United Kingdom is a global management, engineering and development consultancy with more than 14,000 staff, £1 billion revenue and work in 140 countries for the public and private sectors. Mott MacDonald’s core business sectors cover buildings, transport, energy, water, environment, health, education, industry, oil and gas, communications and international development. The company has a significant and growing business in the industry sector and is currently working on a range of major projects in USA, China, Middle East, Russia, Europe and the UK.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM